首页(Home)
品牌专区(Brands-parters)
//自动完成提示
function beginSearch() {
if (document.getElementById("Keyword").value.replace(/(^\s*)|(\s*$)/g, "").length > 2) {
$("#divMsg").html("");
var tbSearch = document.getElementById("Keyword").value;
var div_msg = document.getElementById("divMsg");
div_msg.style.display = "block";
$.ajax({
type: "post",
dataType: "json", //数据格式:JSON
url: "/tools/submit_ajax.ashx?action=zhitishi",
data: { father: tbSearch },
async: false,
success: function (data) {
var str = "";
var str1 = "";
var str2 = "";
var str3 = "";
var SupplyType = data.SupplyType; //供应品类列表
var Brands = data.Brands; //品牌列表
var ProductStyle = data.ProductStyle; //产品列表
var str0 = "";
if (SupplyType != null && SupplyType != "") {
str0 += " 美国Discovery Laboratories www.discoverylabs.com 供应分类";
$.each(SupplyType, function () {//遍历Specification
str0 += "";
});
}
if (ProductStyle != null && ProductStyle != "") {
str1 += "产品分类";
$.each(ProductStyle, function () {//遍历ProductType
str1 += "";
});
}
if (Brands != null && Brands != "") {
str2 = "品牌";
$.each(Brands, function () {//遍历Brands
str2 += "";
});
}
str = str0 + str2 + "";
$("#divMsg").html(str);
}
});
}
else if (document.getElementById("Keyword").value.replace(/(^\s*)|(\s*$)/g, "").length == 0) {
var div_msg = document.getElementById("divMsg");
div_msg.style.display = "none";
div_msg.innerHTML = "";
}
}
Discovery Laboratories公司是美国的一家生物技术公司，运用其KL4表面活性剂和气溶胶毛细血管生成技术，从事表面活性剂疗法的开发，用于治疗呼吸系统疾病。该公司成立于1992年，总部位于宾夕法尼亚州的沃灵顿，拥有91名全职员工。
Discovery Laboratories, Inc. is a specialty biotechnology company with one focus – to advance a new standard in respiratory critical care. Discovery Labs' novel proprietary KL4 surfactant technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant and is being developed in liquid, lyophilized, and aerosolized dosage forms. Discovery Labs is also developing its proprietary drug delivery technologies to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs believes that its proprietary technologies make it possible, for the first time, to develop a significant pipeline of products to address a variety of respiratory diseases for which there frequently are few or no approved therapies.
